Oncology Xagena
New results from a retrospective study suggest that anti-HER2 treatments, like the widely used breast cancer agent Trastuzumab ( Herceptin ), have anti-cancer effects in a small subset of patients wit ...
Results from a retrospective study conducted in Europe suggest that anti-HER2 treatments, like the widely used breast cancer agent Trastuzumab ( Herceptin ), have anti-cancer effects in a small subset ...
Improved disease control with continuation of EGFR inhibition beyond progression has been suggested in retrospective / non-randomized studies, however, this has yet to be prospectively evaluated in a ...
Afatinib ( Giotrif ) is an oral, irreversible ErbB family blocker of EGFR, HER2, ErbB3 and ErbB4 signalling. LUX-Lung 3 ( LL3 ) has compared Afatinib with Cisplatin / Pemetrexed in 345 patients recrui ...
LUX-Lung 1 was a phase IIb/III study that looked at the benefit of Afatinib ( Giotrif ) and best supportive care in comparison with placebo and best supportive care, as a third-line or fourth-line the ...
Afatinib ( Giotrif ) was compared with standard Platinum-based doublet chemotherapy in two large, randomized phase III studies, ie, LUX-Lung 3 and LUX-Lung 6, in patients with EGFR-mutant advanced non ...
A Committee of the American Society of Clinical Oncology NSCLC Expert Panel carried out a systematic review of randomized controlled trials from January 2007 to February 2014 to provide evidence-base ...
